Mucosal	O
Involvement	O
in	O
Bullous	B-DS
Pemphigoid	I-DS
Is	O
Mostly	O
Associated	O
with	O
Disease	O
Severity	O
and	O
to	O
Absence	O
of	O
Anti	O
-	O
BP230	B-GP
Autoantibody	B-GP

Edited	O
by	O
:	O
Ralf	O
J	O
.	O

Ludwig	O
,	O
University	O
of	O
Lübeck	O
,	O
Germany	O

Reviewed	O
by	O
:	O
Hiroshi	O
Koga	O
,	O
Kurume	O
University	O
School	O
of	O
Medicine	O
,	O
Japan	O
;	O
Takashi	O
Hashimoto	O
,	O
Osaka	O
City	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Japan	O

†	O
These	O
authors	O
have	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Specialty	O
section	O
:	O
This	O
article	O
was	O
submitted	O
to	O
Immunological	O
Tolerance	O
and	O
Regulation	O
,	O
a	O
section	O
of	O
the	O
journal	O
Frontiers	O
in	O
Immunology	O

Bullous	B-DS
pemphigoid	I-DS
(	O
BP	B-DS
)	O
is	O
the	O
most	O
common	O
autoimmune	B-DS
bullous	I-DS
disease	I-DS
and	O
typically	O
affects	O
the	O
elderly	O
.	O

Binding	O
of	O
specific	O
autoantibodies	B-GP
to	O
BP180	B-GP
/	O
230	O
hemidesmosomal	O
components	O
induces	O
an	O
inflammatory	O
response	O
leading	O
to	O
skin	O
blister	O
formation	O
.	O

Unusual	O
manifestations	O
of	O
BP	B-DS
include	O
additional	O
mucous	O
membrane	O
involvement	O
,	O
without	O
pathophysiological	O
knowledge	O
associated	O
to	O
the	O
formation	O
of	O
these	O
lesions	O
.	O

We	O
here	O
performed	O
a	O
prospective	O
study	O
on	O
series	O
of	O
consecutive	O
BP	B-DS
patients	O
with	O
(	O
n	O
=	O
77	O
)	O
and	O
without	O
(	O
n	O
=	O
18	O
)	O
mucosal	O
involvements	O
at	O
baseline	O
to	O
further	O
investigate	O
why	O
some	O
BP	B-DS
patients	O
display	O
mucosal	O
lesion	O
and	O
other	O
not	O
.	O

Analysis	O
of	O
disease	O
activity	O
showed	O
that	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
displayed	O
a	O
higher	O
total	O
BP	B-DS
Disease	O
Area	O
Index	O
(	O
BPDAI	O
)	O
score	O
(	O
P	O
=	O
0	O
.	O
008	O
),	O
but	O
also	O
higher	O
skin	O
and	O
blister	O
/	O
erosion	O
BPDAI	O
scores	O
(	O
P	O
=	O
0	O
.	O
02	O
and	O
P	O
=	O
0	O
.	O
001	O
,	O
respectively	O
).	O

By	O
contrast	O
,	O
the	O
erythema	B-DS
/	O
urticaria	B-DS
BPDAI	O
score	O
was	O
identical	O
between	O
the	O
two	O
groups	O
of	O
patients	O
.	O

The	O
erythema	B-DS
/	O
urticaria	B-DS
BPDAI	O
score	O
,	O
but	O
not	O
the	O
blister	O
/	O
erosion	O
BPDAI	O
score	O
,	O
was	O
correlated	O
with	O
the	O
serum	O
concentration	O
of	O
anti	O
-	O
BP180	B-GP
NC16A	O
autoantibodies	B-GP
in	O
patients	O
with	O
mucosal	O
involvement	O
.	O

In	O
multivariate	O
analysis	O
,	O
the	O
absence	O
of	O
anti	O
-	O
BP230	B-GP
autoantibody	B-GP
was	O
the	O
only	O
factor	O
independently	O
associated	O
with	O
mucosal	O
involvement	O
(	O
OR	O
7	O
.	O
8	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
1	O
–	O
19	O
.	O
6	O
)	O
(	O
P	O
<	O
0	O
.	O
0001	O
).	O

Analysis	O
of	O
the	O
distribution	O
of	O
BP	B-DS
patients	O
according	O
to	O
BPDAI	O
scores	O
revealed	O
a	O
shift	O
toward	O
higher	O
blister	O
/	O
erosion	O
BPDAI	O
scores	O
for	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
.	O

This	O
study	O
indicates	O
that	O
mucosal	O
lesions	O
are	O
clinically	O
mainly	O
related	O
to	O
disease	O
severity	O
and	O
immunologically	O
to	O
the	O
absence	O
of	O
anti	O
-	O
BP230	B-GP
antibodies	B-GP
.	O

Introduction	O

Bullous	B-DS
pemphigoid	I-DS
(	O
BP	B-DS
)	O
is	O
an	O
autoimmune	B-DS
skin	I-DS
disease	I-DS
characterized	O
by	O
the	O
binding	O
of	O
autoantibodies	B-GP
directed	O
against	O
two	O
hemidesmosal	O
proteins	O
of	O
the	O
dermal	O
–	O
epidermal	O
junction	O
,	O
namely	O
BP180	B-GP
and	O
BP230	B-GP
(	O
1	O
–	O
6	O
).	O

The	O
disease	O
typically	O
presents	O
in	O
the	O
elderly	O
with	O
a	O
generalized	O
pruritic	O
blistering	O
eruption	O
(	O
7	O
–	O
9	O
),	O
which	O
results	O
from	O
an	O
inflammatory	O
associated	O
disruption	O
of	O
the	O
dermal	O
–	O
epidermal	O
junction	O
induced	O
by	O
the	O
binding	O
of	O
autoantibodies	B-GP
onto	O
their	O
targets	O
.	O

Clinical	O
criteria	O
for	O
typical	O
skin	O
eruption	O
of	O
BP	B-DS
include	O
the	O
absence	O
of	O
associated	O
external	O
mucous	O
membrane	O
(	O
almost	O
exclusively	O
oral	O
)	O
involvement	O
,	O
the	O
absence	O
of	O
skin	B-DS
atrophy	I-DS
,	O
and	O
the	O
absence	O
of	O
head	O
and	O
neck	O
predominant	O
involvement	O
(	O
10	O
).	O

However	O
,	O
clinical	O
presentation	O
of	O
BP	B-DS
can	O
be	O
polymorphic	O
,	O
notably	O
during	O
the	O
early	O
,	O
pre	O
-	O
bullous	O
stage	O
of	O
the	O
disease	O
or	O
in	O
atypical	O
variants	O
,	O
in	O
which	O
full	O
-	O
blown	O
bullous	O
lesions	O
may	O
be	O
absent	O
(	O
11	O
,	O
12	O
).	O

Beside	O
,	O
blisters	O
and	O
erosions	O
arising	O
on	O
mucosal	O
membranes	O
,	O
mainly	O
within	O
the	O
oral	O
cavity	O
,	O
may	O
be	O
observed	O
in	O
up	O
to	O
20	O
%	O
of	O
BP	B-DS
patients	O
(	O
6	O
,	O
11	O
–	O
13	O
),	O
without	O
identified	O
pathophysiologic	O
mechanism	O
(	O
s	O
)	O
associated	O
with	O
their	O
development	O
.	O

Despite	O
the	O
interest	O
of	O
the	O
research	O
community	O
in	O
always	O
better	O
understanding	O
BP	B-DS
pathophysiology	O
,	O
no	O
study	O
demonstrated	O
whether	O
mucosal	O
involvement	O
occurred	O
as	O
a	O
consequence	O
of	O
BP	B-DS
extent	O
and	O
severity	O
or	O
whether	O
skin	O
and	O
mucosal	O
lesions	O
occurred	O
concomitantly	O
.	O

Recently	O
a	O
clinical	O
activity	O
score	O
named	O
BP	B-DS
Disease	O
Area	O
Index	O
(	O
BPDAI	O
)	O
was	O
proposed	O
as	O
an	O
international	O
consensus	O
to	O
evaluate	O
both	O
the	O
disease	O
extent	O
and	O
the	O
location	O
and	O
type	O
of	O
skin	B-DS
lesions	I-DS
(	O
9	O
).	O

The	O
BPDAI	O
also	O
has	O
the	O
advantage	O
to	O
measure	O
separate	O
scores	O
for	O
skin	O
and	O
mucous	O
membrane	O
activity	O
.	O

Besides	O
,	O
the	O
skin	O
BPDAI	O
score	O
also	O
evaluates	O
separately	O
the	O
ultimate	O
skin	B-DS
lesions	I-DS
,	O
i	O
.	O
e	O
.,	O
blisters	O
/	O
erosions	O
,	O
and	O
the	O
early	O
,	O
pre	B-DS
-	I-DS
bullous	I-DS
inflammatory	I-DS
skin	I-DS
lesions	I-DS
,	O
i	O
.	O
e	O
.,	O
urticaria	B-DS
/	O
erythema	B-DS
,	O
and	O
their	O
extent	O
as	O
well	O
as	O
the	O
residual	O
damages	O
.	O

Thus	O
,	O
such	O
specific	O
clinical	O
score	O
may	O
be	O
useful	O
to	O
better	O
characterize	O
those	O
BP	B-DS
patients	O
with	O
associated	O
mucosal	O
involvement	O
and	O
improve	O
their	O
monitoring	O
.	O

Immunological	O
and	O
biological	O
investigations	O
in	O
BP	B-DS
brought	O
strong	O
evidence	O
that	O
autoantibodies	B-GP
to	O
BP180	B-GP
are	O
pathogenic	O
and	O
play	O
a	O
key	O
role	O
in	O
subepidermal	O
blister	O
formation	O
(	O
14	O
–	O
20	O
).	O

Biopsy	O
specimens	O
from	O
BP	B-DS
lesional	O
skin	O
exhibit	O
dense	O
inflammatory	O
infiltration	O
of	O
eosinophils	O
,	O
basophils	O
,	O
neutrophils	O
,	O
lymphocytes	O
,	O
and	O
mast	O
cells	O
in	O
the	O
dermis	O
(	O
1	O
,	O
11	O
,	O
13	O
,	O
21	O
,	O
22	O
).	O

Inflammatory	O
cells	O
infiltration	O
and	O
activation	O
release	O
cytokines	B-GP
and	O
proteases	B-GP
that	O
may	O
create	O
an	O
auto	O
-	O
amplification	O
loop	O
reported	O
to	O
induce	O
dermal	O
–	O
epidermal	O
separation	O
(	O
23	O
–	O
27	O
).	O

However	O
,	O
variations	O
in	O
this	O
pathophysiological	O
process	O
are	O
still	O
missing	O
to	O
explain	O
why	O
some	O
BP	B-DS
patients	O
will	O
exhibit	O
mucosal	O
involvement	O
and	O
other	O
not	O
.	O

In	O
this	O
matter	O
,	O
a	O
more	O
precise	O
clinical	O
characterization	O
of	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
may	O
help	O
to	O
point	O
out	O
variations	O
in	O
the	O
autoimmune	O
and	O
inflammatory	O
responses	O
in	O
this	O
particular	O
BP	B-DS
subset	O
.	O

We	O
here	O
performed	O
a	O
prospective	O
study	O
on	O
series	O
of	O
consecutive	O
BP	B-DS
patients	O
with	O
and	O
without	O
mucosal	O
involvement	O
.	O

To	O
further	O
understand	O
why	O
some	O
BP	B-DS
patients	O
display	O
mucosal	O
blisters	O
or	O
erosions	O
and	O
other	O
not	O
,	O
we	O
compared	O
the	O
total	O
BPDAI	O
and	O
its	O
different	O
components	O
with	O
other	O
clinical	O
and	O
immunological	O
parameters	O
of	O
disease	O
activity	O
at	O
baseline	O
,	O
including	O
the	O
number	O
of	O
daily	O
new	O
blisters	O
and	O
the	O
anti	O
-	O
BP180	B-GP
and	O
anti	O
-	O
BP230	B-GP
autoantibody	B-GP
titers	O
.	O

Materials	O
and	O
Methods	O

Study	O
Patients	O
and	O
Design	O

A	O
prospective	O
,	O
single	O
-	O
center	O
study	O
was	O
conducted	O
in	O
the	O
Dermatology	O
Department	O
of	O
the	O
Reims	O
University	O
Hospital	O
(	O
French	O
Referral	O
Center	O
for	O
Autoimmune	O
Bullous	O
Diseases	O
)	O
between	O
September	O
2013	O
and	O
July	O
2017	O
.	O

The	O
investigation	O
was	O
conducted	O
under	O
the	O
approval	O
of	O
the	O
Ethic	O
Committee	O
of	O
the	O
University	O
Hospital	O
of	O
Reims	O
(	O
CNIL	O
authorization	O
DR	O
-	O
2013	O
-	O
320	O
),	O
and	O
all	O
of	O
the	O
subjects	O
gave	O
their	O
informed	O
and	O
written	O
consent	O
before	O
participating	O
in	O
the	O
study	O
in	O
accordance	O
with	O
the	O
Helsinki	O
Declaration	O
.	O

Consecutive	O
patients	O
with	O
newly	O
diagnosed	O
BP	B-DS
were	O
included	O
in	O
this	O
prospective	O
study	O
.	O

Patients	O
were	O
diagnosed	O
as	O
having	O
BP	B-DS
using	O
the	O
following	O
criteria	O
:	O
clinical	O
features	O
typical	O
of	O
BP	B-DS
with	O
the	O
presence	O
of	O
at	O
least	O
three	O
of	O
four	O
well	O
-	O
established	O
criteria	O
according	O
to	O
Vaillant	O
et	O
al	O
.	O
(	O
10	O
);	O
subepidermal	O
blister	O
on	O
skin	O
biopsy	O
,	O
and	O
deposits	O
of	O
IgG	B-GP
and	O
/	O
or	O
C3	B-GP
in	O
a	O
linear	O
pattern	O
along	O
the	O
epidermal	O
basement	O
membrane	O
zone	O
by	O
direct	O
immunofluorescence	O
.	O

Non	O
-	O
inclusion	O
criteria	O
were	O
administration	O
of	O
a	O
specific	O
BP	B-DS
treatment	O
for	O
more	O
than	O
2	O
days	O
,	O
pregnancy	O
and	O
expected	O
survival	O
after	O
BP	B-DS
diagnosis	O
shorter	O
than	O
3	O
months	O
.	O

Clinical	O
Data	O
Collection	O

Clinical	O
data	O
recorded	O
at	O
baseline	O
were	O
gender	O
,	O
age	O
,	O
number	O
of	O
daily	O
new	O
blisters	O
(	O
determined	O
over	O
a	O
3	O
-	O
day	O
period	O
),	O
and	O
BPDAI	O
.	O

BPDAI	O
was	O
calculated	O
according	O
to	O
the	O
International	O
Pemphigoid	B-DS
Committee	O
recommendations	O
(	O
9	O
).	O

At	O
baseline	O
,	O
BPDAI	O
was	O
recorded	O
.	O

The	O
total	O
BPDAI	O
computes	O
two	O
scores	O
:	O
total	O
BPDAI	O
activity	O
and	O
total	O
BPDAI	O
damage	O
.	O

The	O
total	O
BPDAI	O
activity	O
score	O
is	O
the	O
arithmetic	O
sum	O
of	O
the	O
three	O
subcomponents	O
—	O
cutaneous	O
blisters	O
/	O
erosions	O
,	O
cutaneous	O
urticaria	B-DS
/	O
erythema	B-DS
,	O
and	O
mucosal	O
blisters	O
/	O
erosions	O
.	O

The	O
total	O
BPDAI	O
damage	O
score	O
is	O
the	O
arithmetic	O
sum	O
of	O
the	O
items	O
rated	O
regionally	O
for	O
damage	O
caused	O
by	O
more	O
permanent	O
features	O
such	O
as	O
post	O
-	O
inflammatory	O
hyperpigmentation	O
,	O
scarring	O
,	O
and	O
other	O
.	O

BPDAI	O
also	O
takes	O
into	O
account	O
lesion	O
number	O
and	O
size	O
thresholds	O
and	O
skin	B-DS
lesions	I-DS
are	O
rated	O
based	O
on	O
the	O
regions	O
affected	O
.	O

Scores	O
can	O
range	O
from	O
0	O
to	O
360	O
for	O
BPDAI	O
total	O
activity	O
(	O
maximum	O
240	O
for	O
total	O
skin	O
activity	O
and	O
120	O
for	O
mucosal	O
activity	O
)	O
and	O
0	O
to	O
12	O
for	O
BPDAI	O
damage	O
,	O
with	O
higher	O
scores	O
indicating	O
greater	O
disease	O
activity	O
or	O
damage	O
.	O

On	O
the	O
basis	O
of	O
previous	O
literature	O
(	O
28	O
),	O
severe	O
BP	B-DS
at	O
baseline	O
was	O
defined	O
as	O
a	O
total	O
BPDAI	O
score	O
≥	O
56	O
.	O

BP	B-DS
patients	O
who	O
did	O
not	O
fulfill	O
these	O
criteria	O
were	O
classified	O
as	O
having	O
moderate	O
BP	B-DS
.	O

Anti	O
-	O
BP180	B-GP
and	O
Anti	O
-	O
BP230	B-GP
Autoantibody	B-GP
Detection	O

Anti	O
-	O
BP180	B-GP
and	O
anti	O
-	O
BP230	B-GP
autoantibodies	B-GP
were	O
detected	O
in	O
serum	O
and	O
in	O
blister	O
fluids	O
(	O
BFs	O
)	O
using	O
specific	O
commercially	O
available	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
(	O
ELISAs	O
)	O
following	O
the	O
manufacturer	O
’	O
s	O
instructions	O
(	O
MBL	O
,	O
Nagoya	O
,	O
Japan	O
).	O

Anti	O
-	O
BP180	B-GP
and	O
anti	O
-	O
BP230	B-GP
antibodies	B-GP
’	O
detection	O
was	O
routinely	O
performed	O
on	O
classically	O
used	O
dilution	O
with	O
no	O
further	O
dilution	O
when	O
titers	O
were	O
high	O
.	O

ELISA	O
values	O
were	O
expressed	O
as	O
units	O
per	O
milliliters	O
of	O
serum	O
(	O
U	O
/	O
mL	O
),	O
and	O
the	O
9	O
U	O
/	O
mL	O
cut	O
-	O
off	O
value	O
recommended	O
by	O
the	O
manufacturer	O
was	O
used	O
in	O
both	O
anti	O
-	O
BP180	B-GP
and	O
anti	O
-	O
BP230	B-GP
ELISAs	O
(	O
29	O
–	O
32	O
).	O

Statistical	O
Analysis	O

Quantitative	O
variables	O
were	O
described	O
as	O
mean	O
±	O
SD	O
and	O
qualitative	O
data	O
as	O
number	O
and	O
percentage	O
.	O

Kolmogorov	O
–	O
Smirnov	O
test	O
was	O
performed	O
to	O
compare	O
BP	B-DS
population	O
distribution	O
.	O

The	O
Kolmogorov	O
–	O
Smirnov	O
test	O
works	O
by	O
comparing	O
the	O
cumulative	O
distribution	O
of	O
the	O
two	O
data	O
sets	O
and	O
computes	O
a	O
P	O
value	O
that	O
depends	O
on	O
the	O
largest	O
discrepancy	O
between	O
distributions	O
.	O

In	O
contrast	O
to	O
Mann	O
–	O
Whitney	O
test	O
that	O
is	O
mostly	O
sensitive	O
to	O
changes	O
in	O
the	O
median	O
,	O
the	O
Kolmogorov	O
–	O
Smirnov	O
test	O
is	O
sensitive	O
to	O
changes	O
in	O
the	O
shape	O
,	O
spread	O
,	O
or	O
median	O
of	O
the	O
two	O
distributions	O
.	O

Chi2	O
tests	O
were	O
used	O
for	O
comparison	O
between	O
qualitative	O
variables	O
and	O
nonparametric	O
,	O
Mann	O
–	O
Whitney	O
tests	O
for	O
comparison	O
between	O
quantitative	O
values	O
.	O

Owing	O
to	O
absence	O
of	O
normal	O
distribution	O
,	O
comparisons	O
between	O
groups	O
were	O
performed	O
using	O
Spearman	O
’	O
s	O
correlation	O
coefficient	O
to	O
explore	O
the	O
relationship	O
between	O
continuous	O
variables	O
(	O
BPDAI	O
with	O
immunological	O
parameters	O
,	O
immunological	O
parameters	O
in	O
serum	O
with	O
those	O
in	O
BF	O
).	O

A	O
P	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
statistically	O
significant	O
.	O

Multivariate	O
analyses	O
were	O
then	O
performed	O
using	O
stepwise	O
logistic	O
regressions	O
,	O
with	O
enter	O
and	O
removal	O
limits	O
set	O
at	O
0	O
.	O
20	O
and	O
factors	O
significant	O
at	O
P	O
=	O
0	O
.	O
20	O
included	O
.	O

Results	O

Patient	O
Characteristics	O

A	O
total	O
of	O
97	O
patients	O
with	O
newly	O
diagnosed	O
BP	B-DS
were	O
included	O
in	O
this	O
study	O
,	O
79	O
had	O
typical	O
clinical	O
manifestations	O
of	O
BP	B-DS
and	O
18	O
presented	O
with	O
mucosal	O
lesions	O
in	O
additional	O
to	O
skin	O
blisters	O
or	O
erosions	O
.	O

In	O
those	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
,	O
indirect	O
immunofluorescence	O
on	O
salt	O
-	O
split	O
skin	O
was	O
either	O
positive	O
with	O
labeling	O
of	O
the	O
epidermal	O
side	O
of	O
the	O
cleavage	O
or	O
negative	O
.	O

Using	O
the	O
same	O
technique	O
,	O
two	O
patients	O
with	O
positive	O
immunolabeling	O
on	O
the	O
dermal	O
side	O
only	O
were	O
subsequently	O
excluded	O
from	O
the	O
group	O
with	O
typical	O
clinical	O
BP	B-DS
presentation	O
.	O

The	O
clinical	O
characteristics	O
of	O
those	O
77	O
patients	O
with	O
typical	O
BP	B-DS
features	O
(	O
81	O
%,	O
51	O
women	O
and	O
26	O
men	O
)	O
and	O
of	O
the	O
18	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
(	O
19	O
%,	O
11	O
women	O
and	O
7	O
men	O
)	O
are	O
shown	O
in	O
Table	O
1	O
.	O

In	O
the	O
18	O
BP	B-DS
patients	O
with	O
unconventional	O
mucosal	O
involvement	O
,	O
oral	O
mucosal	O
lesions	O
were	O
observed	O
in	O
17	O
cases	O
and	O
anogenital	O
mucosae	O
lesions	O
in	O
1	O
case	O
.	O

Among	O
the	O
17	O
patients	O
with	O
oral	O
lesions	O
,	O
1	O
patient	O
also	O
displayed	O
anogenital	O
mucosae	O
involvement	O
,	O
and	O
another	O
1	O
had	O
concomitant	O
pharyngeal	O
mucosa	O
lesions	O
.	O

In	O
those	O
18	O
BP	B-DS
patients	O
,	O
neither	O
conjunctival	O
nor	O
nasal	O
mucosa	O
involvement	O
was	O
observed	O
.	O

Occurrence	O
of	O
mucosal	O
lesions	O
was	O
correlated	O
neither	O
with	O
the	O
gender	O
(	O
P	O
=	O
0	O
.	O
78	O
)	O
nor	O
with	O
the	O
age	O
(	O
P	O
=	O
0	O
.	O
24	O
)	O
of	O
patients	O
.	O

Clinical	O
characteristics	O
of	O
patients	O
with	O
BP	B-DS
according	O
to	O
mucosal	O
involvement	O
.	O

All	O
BP	B-DS
patients	O

Patients	O
without	O
mucosal	O
involvement	O

Patients	O
with	O
mucosal	O
involvement	O

Pvalue	O

Number	O
of	O
patients	O
(	O
n	O
)	O

95	O

77	O

18	O

NA	O

Sex	O
ratio	O
(	O
F	O
/	O
M	O
)	O

1	O
.	O
88	O

1	O
.	O
96	O

1	O
.	O
57	O

0	O
.	O
68	O

Age	O
,	O
mean	O
±	O
SD	O

81	O
.	O
7	O
±	O
9	O
.	O
3	O

82	O
.	O
4	O
±	O
8	O
.	O
9	O

78	O
.	O
7	O
±	O
10	O
.	O
6	O

0	O
.	O
18	O

Patients	O
with	O
at	O
least	O
10	O
daily	O
new	O
blisters	O
,	O
a	O
n	O
(%)	O

45	O
(	O
47	O
.	O
4	O
)	O

32	O
(	O
41	O
.	O
6	O
)	O

13	O
(	O
72	O
.	O
2	O
)	O

0	O
.	O
02	O

Number	O
of	O
daily	O
new	O
blisters	O
,	O
a	O
mean	O
±	O
SD	O

19	O
.	O
3	O
±	O
29	O
.	O
8	O

17	O
.	O
6	O
±	O
27	O
.	O
1	O

26	O
.	O
5	O
±	O
39	O
.	O
4	O

0	O
.	O
07	O

BPDAI	O
global	O
score	O
,	O
mean	O
±	O
SD	O

39	O
.	O
6	O
±	O
27	O

35	O
.	O
8	O
±	O
25	O
.	O
1	O

56	O
.	O
1	O
±	O
29	O
.	O
2	O

0	O
.	O
008	O

Activity	O
of	O
total	O
skin	O
involvement	O
,	O
mean	O
±	O
SD	O

38	O
.	O
1	O
±	O
26	O

35	O
.	O
1	O
±	O
25	O

51	O
.	O
0	O
±	O
26	O
.	O
8	O

0	O
.	O
021	O

Blisters	O
/	O
erosions	O
,	O
mean	O
±	O
SD	O

24	O
.	O
9	O
±	O
17	O
.	O
6	O

22	O
.	O
1	O
±	O
16	O
.	O
4	O

36	O
.	O
9	O
±	O
17	O
.	O
6	O

0	O
.	O
001	O

Erythema	B-DS
/	O
urticaria	B-DS
,	O
mean	O
±	O
SD	O

13	O
.	O
2	O
±	O
13	O
.	O
6	O

13	O
±	O
13	O
.	O
3	O

14	O
.	O
1	O
±	O
15	O
.	O
1	O

0	O
.	O
91	O

Activity	O
of	O
mucosal	O
involvement	O
,	O
mean	O
±	O
SD	O

0	O
.	O
8	O
±	O
2	O
.	O
4	O

0	O

4	O
.	O
0	O
±	O
4	O
.	O
2	O

NA	O

Damage	O
,	O
mean	O
±	O
SD	O

0	O
.	O
8	O
±	O
2	O

0	O
.	O
7	O
±	O
1	O
.	O
8	O

1	O
.	O
1	O
±	O
2	O
.	O
6	O

0	O
.	O
78	O

Patients	O
with	O
severe	O
disease	O
according	O
BPDAI	O
,	O
b	O
n	O
(%)	O

24	O
(	O
25	O
)	O

16	O
(	O
20	O
.	O
8	O
)	O

8	O
(	O
44	O
.	O
4	O
)	O

0	O
.	O
04	O

Subsets	O
of	O
BP	B-DS
patients	O
with	O
or	O
without	O
mucosal	O
involvement	O
were	O
compared	O
and	O
P	O
-	O
value	O
was	O
obtained	O
using	O
Chi2	O
tests	O
for	O
comparison	O
between	O
qualitative	O
variables	O
and	O
nonparametric	O
,	O
Mann	O
–	O
Whitney	O
tests	O
for	O
comparison	O
between	O
quantitative	O
values	O
.	O

aDetermined	O
over	O
a	O
3	O
-	O
day	O
period	O
.	O

bDetermined	O
by	O
BPDAI	O
global	O
score	O
≥	O
56	O
.	O

NA	O
,	O
not	O
applicable	O
;	O
BP	B-DS
,	O
bullous	B-DS
pemphigoid	I-DS
;	O
BPDAI	O
,	O
BP	B-DS
Disease	O
Area	O
Index	O
.	O

Skin	B-DS
Disease	I-DS
Activity	O
and	O
Mucosal	O
Involvement	O

At	O
the	O
time	O
of	O
diagnosis	O
,	O
the	O
number	O
of	O
patients	O
with	O
at	O
least	O
10	O
daily	O
new	O
blisters	O
was	O
significantly	O
higher	O
in	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
compared	O
with	O
patients	O
with	O
typical	O
BP	B-DS
(	O
Table	O
1	O
),	O
whereas	O
the	O
number	O
of	O
daily	O
new	O
blisters	O
only	O
tended	O
to	O
be	O
higher	O
in	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
(	O
P	O
=	O
0	O
.	O
07	O
).	O

Total	O
BPDAI	O
mean	O
score	O
was	O
39	O
.	O
6	O
±	O
27	O
at	O
baseline	O
in	O
the	O
whole	O
BP	B-DS
population	O
(	O
Table	O
1	O
).	O

Based	O
on	O
a	O
cut	O
-	O
off	O
BPDAI	O
value	O
of	O
56	O
(	O
see	O
Materials	O
and	O
Methods	O
),	O
the	O
percentage	O
of	O
BP	B-DS
patients	O
with	O
a	O
severe	O
disease	O
was	O
significantly	O
lower	O
in	O
BP	B-DS
patients	O
without	O
mucosal	O
involvement	O
(	O
20	O
.	O
8	O
%)	O
as	O
compared	O
to	O
those	O
with	O
mucosal	O
involvement	O
(	O
44	O
.	O
4	O
%)	O
(	O
Table	O
1	O
;	O
P	O
=	O
0	O
.	O
04	O
).	O

Deeper	O
analysis	O
showed	O
that	O
compared	O
with	O
BP	B-DS
patients	O
with	O
a	O
typical	O
disease	O
,	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
displayed	O
a	O
higher	O
total	O
BPDAI	O
score	O
(	O
Table	O
1	O
;	O
P	O
=	O
0	O
.	O
008	O
),	O
but	O
also	O
higher	O
skin	O
BPDAI	O
and	O
blister	O
/	O
erosion	O
BPDAI	O
scores	O
(	O
Table	O
1	O
;	O
P	O
=	O
0	O
.	O
021	O
and	O
P	O
=	O
0	O
.	O
001	O
,	O
respectively	O
).	O

By	O
contrast	O
,	O
the	O
erythema	B-DS
/	O
urticaria	B-DS
BPDAI	O
score	O
was	O
not	O
different	O
between	O
those	O
two	O
groups	O
of	O
patients	O
(	O
Table	O
1	O
;	O
P	O
=	O
0	O
.	O
91	O
).	O

Analysis	O
of	O
the	O
whole	O
BP	B-DS
population	O
distribution	O
according	O
to	O
BPDAI	O
score	O
revealed	O
that	O
most	O
patients	O
had	O
a	O
mild	O
to	O
moderate	O
disease	O
and	O
that	O
the	O
higher	O
the	O
BPDAI	O
was	O
,	O
the	O
lower	O
the	O
number	O
of	O
BP	B-DS
patients	O
was	O
(	O
Figure	O
1A	O
).	O

Such	O
a	O
distribution	O
was	O
also	O
observed	O
for	O
BP	B-DS
patients	O
without	O
mucosal	O
involvement	O
(	O
Figure	O
1B	O
),	O
but	O
was	O
significantly	O
different	O
in	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
(	O
D	O
=	O
0	O
.	O
6154	O
;	O
P	O
=	O
0	O
.	O
008	O
).	O

Indeed	O
,	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
were	O
evenly	O
distributed	O
from	O
moderate	O
to	O
severe	O
disease	O
(	O
Figure	O
1C	O
).	O

To	O
further	O
understand	O
these	O
discrepancies	O
,	O
the	O
same	O
analysis	O
was	O
then	O
performed	O
using	O
the	O
separate	O
skin	O
activity	O
.	O

The	O
relative	O
distribution	O
according	O
to	O
the	O
erythema	B-DS
/	O
urticaria	B-DS
BPDAI	O
score	O
of	O
BP	B-DS
patients	O
without	O
mucosal	O
involvement	O
superposed	O
with	O
the	O
one	O
of	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
(	O
D	O
=	O
0	O
.	O
1667	O
;	O
P	O
=	O
0	O
.	O
991	O
)	O
(	O
Figure	O
2A	O
).	O

Analysis	O
of	O
the	O
distribution	O
according	O
to	O
the	O
blisters	O
/	O
erosions	O
BPDAI	O
revealed	O
a	O
high	O
percentage	O
of	O
patients	O
with	O
mucosal	O
involvement	O
when	O
the	O
BPDAI	O
values	O
increased	O
and	O
a	O
low	O
percentage	O
of	O
those	O
patients	O
when	O
the	O
BPDAI	O
values	O
were	O
low	O
(	O
D	O
=	O
0	O
.	O
33	O
;	O
P	O
=	O
0	O
.	O
433	O
)	O
(	O
Figure	O
2B	O
).	O

Distribution	O
of	O
the	O
whole	O
bullous	B-DS
pemphigoid	I-DS
(	O
BP	B-DS
)	O
patients	O
(	O
n	O
=	O
95	O
)	O
(	O
A	O
)	O
and	O
of	O
BP	B-DS
patients	O
without	O
(	O
n	O
=	O
77	O
)	O
(	O
B	O
)	O
and	O
with	O
(	O
n	O
=	O
18	O
)	O
(	O
C	O
)	O
mucosal	O
involvement	O
according	O
to	O
total	O
BP	B-DS
Disease	O
Area	O
Index	O
(	O
BPDAI	O
)	O
values	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

In	O
the	O
whole	O
BP	B-DS
group	O
and	O
in	O
the	O
subgroup	O
of	O
BP	B-DS
without	O
mucosal	O
involvement	O
,	O
the	O
number	O
of	O
BP	B-DS
included	O
decrease	O
when	O
the	O
values	O
of	O
the	O
BPDAI	O
increased	O
,	O
whereas	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
were	O
evenly	O
distributed	O
.	O

Comparison	O
of	O
the	O
cumulative	O
distribution	O
by	O
the	O
Kolmogorov	O
–	O
Smirnov	O
test	O
showed	O
significant	O
difference	O
between	O
BP	B-DS
patients	O
with	O
(	O
C	O
)	O
and	O
without	O
(	O
B	O
)	O
mucosal	O
involvement	O
(	O
D	O
=	O
0	O
.	O
6154	O
;	O
P	O
=	O
0	O
.	O
008	O
).	O

Distribution	O
of	O
both	O
bullous	B-DS
pemphigoid	I-DS
(	O
BP	B-DS
)	O
patients	O
with	O
(	O
white	O
column	O
)	O
and	O
without	O
(	O
gray	O
column	O
)	O
mucosal	O
involvement	O
according	O
to	O
erythema	B-DS
/	O
urticaria	B-DS
BP	B-DS
Disease	O
Area	O
Index	O
(	O
BPDAI	O
)	O
values	O
(	O
A	O
)	O
and	O
blisters	O
/	O
erosions	O
BPDAI	O
values	O
(	O
B	O
)	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

No	O
statistical	O
differences	O
were	O
observed	O
between	O
the	O
distributions	O
of	O
these	O
two	O
BP	B-DS
groups	O
according	O
to	O
the	O
Kolmogorov	O
–	O
Smirnov	O
test	O
,	O
although	O
a	O
clear	O
different	O
distribution	O
could	O
be	O
visualized	O
within	O
the	O
low	O
(	O
0	O
–	O
19	O
)	O
and	O
within	O
the	O
high	O
(	O
50	O
–	O
79	O
)	O
values	O
of	O
the	O
blisters	O
/	O
erosions	O
BPDAI	O
values	O
(	O
B	O
).	O

Immunological	O
Profiles	O
and	O
Mucosal	O
Involvement	O

In	O
the	O
aim	O
to	O
analyze	O
the	O
clinical	O
features	O
through	O
the	O
BPDAI	O
scores	O
with	O
regards	O
to	O
the	O
autoimmune	O
response	O
,	O
we	O
first	O
measured	O
anti	O
-	O
BP180	B-GP
and	O
anti	O
-	O
BP230	B-GP
autoantibody	B-GP
concentrations	O
in	O
the	O
BF	O
of	O
patients	O
with	O
BP	B-DS
.	O

Anti	O
-	O
BP180	B-GP
and	O
anti	O
-	O
BP230	B-GP
antibodies	B-GP
were	O
detected	O
in	O
the	O
BF	O
of	O
32	O
(	O
86	O
.	O
5	O
%)	O
and	O
16	O
(	O
43	O
.	O
2	O
%)	O
patients	O
with	O
a	O
mean	O
titer	O
of	O
79	O
.	O
4	O
±	O
51	O
.	O
2	O
and	O
31	O
.	O
2	O
±	O
40	O
.	O
3	O
U	O
/	O
mL	O
,	O
respectively	O
(	O
Table	O
2A	O
).	O

Subgroup	O
analysis	O
of	O
BP	B-DS
patients	O
with	O
and	O
without	O
mucosal	O
involvement	O
showed	O
no	O
significant	O
difference	O
both	O
within	O
the	O
number	O
of	O
BP	B-DS
patients	O
who	O
produced	O
these	O
antibodies	B-GP
and	O
within	O
the	O
mean	O
BF	O
titer	O
related	O
to	O
each	O
antibody	B-GP
.	O

We	O
then	O
investigated	O
whether	O
serum	O
autoantibody	B-GP
concentrations	O
reflected	O
those	O
measured	O
in	O
the	O
BF	O
of	O
the	O
same	O
patients	O
to	O
seek	O
a	O
relationship	O
between	O
BPDAI	O
scores	O
and	O
autoantibody	B-GP
production	O
in	O
the	O
whole	O
BP	B-DS
patients	O
included	O
.	O

Anti	O
-	O
BP180	B-GP
and	O
anti	O
-	O
BP230	B-GP
antibodies	B-GP
titers	O
within	O
the	O
BF	O
were	O
highly	O
and	O
significantly	O
correlated	O
with	O
those	O
measured	O
in	O
the	O
serum	O
(	O
r	O
=	O
0	O
.	O
78	O
and	O
r	O
=	O
0	O
.	O
73	O
;	O
P	O
<	O
0	O
.	O
0001	O
,	O
respectively	O
)	O
(	O
Table	O
2B	O
).	O

Such	O
a	O
correlation	O
was	O
also	O
found	O
for	O
the	O
anti	O
-	O
BP180	B-GP
antibody	B-GP
titers	O
within	O
the	O
two	O
subsets	O
of	O
patients	O
with	O
or	O
without	O
mucosal	O
involvement	O
(	O
r	O
=	O
0	O
.	O
74	O
and	O
r	O
=	O
0	O
.	O
89	O
;	O
P	O
<	O
0	O
.	O
0001	O
and	O
P	O
=	O
0	O
.	O
01	O
,	O
respectively	O
)	O
(	O
Table	O
2B	O
).	O

Anti	O
-	O
BP230	B-GP
antibody	B-GP
titers	O
in	O
BF	O
from	O
typical	O
BP	B-DS
patients	O
were	O
highly	O
and	O
significantly	O
correlated	O
with	O
those	O
measured	O
in	O
the	O
serum	O
of	O
these	O
patients	O
(	O
r	O
=	O
0	O
.	O
74	O
;	O
P	O
<	O
0	O
.	O
0001	O
),	O
whereas	O
only	O
a	O
high	O
tendency	O
was	O
found	O
for	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
(	O
r	O
=	O
0	O
.	O
75	O
;	O
P	O
=	O
0	O
.	O
07	O
)	O
(	O
Table	O
2B	O
).	O

Blister	O
fluid	O
(	O
BF	O
)	O
immunological	O
characteristics	O
(	O
A	O
)	O
and	O
correlation	O
between	O
serum	O
and	O
BF	O
autoantibody	B-GP
titers	O
(	O
B	O
)	O
in	O
patients	O
with	O
BP	B-DS
according	O
to	O
mucosal	O
involvement	O
.	O

All	O
BP	B-DS
patients	O

Patients	O
without	O
mucosal	O
involvement	O

Patients	O
with	O
mucosal	O
involvement	O

Pvalue	O

(	O
A	O
)	O


Number	O
of	O
patients	O
(	O
n	O
)	O
a	O

37	O

30	O

7	O

NA	O

BF	O
anti	O
-	O
BP180	B-GP
NC16A	O

Number	O
of	O
patients	O
with	O
titer	O
≥	O
9	O
U	O
/	O
mL	O
,	O
n	O
(%)	O

32	O
(	O
86	O
.	O
5	O
)	O

26	O
(	O
86	O
.	O
7	O
)	O

6	O
(	O
85	O
.	O
7	O
)	O

0	O
.	O
95	O

Mean	O
value	O
±	O
SD	O
(	O
U	O
/	O
mL	O
)	O

79	O
.	O
4	O
±	O
51	O
.	O
2	O

78	O
.	O
5	O
±	O
51	O
.	O
8	O

83	O
.	O
5	O
±	O
52	O
.	O
2	O

0	O
.	O
66	O

BF	O
anti	O
-	O
BP230	B-GP

Number	O
of	O
patients	O
with	O
titer	O
≥	O
9	O
U	O
/	O
mL	O
,	O
n	O
(%)	O

16	O
(	O
43	O
.	O
2	O
)	O

14	O
(	O
46	O
.	O
7	O
)	O

2	O
(	O
28	O
.	O
7	O
)	O

0	O
.	O
38	O

Mean	O
value	O
±	O
SD	O
(	O
U	O
/	O
mL	O
)	O

31	O
.	O
2	O
±	O
40	O
.	O
3	O

34	O
.	O
2	O
±	O
41	O
.	O
5	O

18	O
.	O
2	O
±	O
34	O
.	O
2	O

0	O
.	O
65	O


(	O
B	O
)	O


Number	O
of	O
patientsa	O

37	O

30	O

7	O

Anti	O
-	O
BP180	B-GP
NC16A	O

r	O
=	O
0	O
.	O
78	O

r	O
=	O
0	O
.	O
74	O

r	O
=	O
0	O
.	O
89	O

P	O
<	O
0	O
.	O
0001	O

P	O
<	O
0	O
.	O
0001	O

P	O
=	O
0	O
.	O
01	O

Anti	O
-	O
BP230	B-GP

r	O
=	O
0	O
.	O
73	O

r	O
=	O
0	O
.	O
74	O

r	O
=	O
0	O
.	O
75	O

P	O
<	O
0	O
.	O
0001	O

P	O
<	O
0	O
.	O
0001	O

P	O
=	O
0	O
.	O
07	O

Subsets	O
of	O
BP	B-DS
patients	O
with	O
or	O
without	O
mucosal	O
involvement	O
were	O
compared	O
and	O
P	O
-	O
value	O
was	O
calculated	O
using	O
Chi2	O
tests	O
for	O
comparison	O
between	O
qualitative	O
variables	O
and	O
nonparametric	O
,	O
Mann	O
–	O
Whitney	O
tests	O
for	O
comparison	O
between	O
quantitative	O
values	O
.	O

Spearman	O
’	O
s	O
correlation	O
coefficient	O
was	O
used	O
to	O
explore	O
the	O
relationship	O
between	O
immunological	O
parameters	O
in	O
serum	O
with	O
those	O
in	O
BF	O
.	O

aPatient	O
for	O
whom	O
BF	O
and	O
serum	O
anti	O
-	O
BP180	B-GP
NC16A	O
and	O
anti	O
-	O
BP230	B-GP
ELISA	O
values	O
were	O
available	O
.	O

NA	O
,	O
not	O
applicable	O
;	O
BP	B-DS
,	O
bullous	B-DS
pemphigoid	I-DS
;	O
ELISA	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Anti	O
-	O
BP180	B-GP
antibodies	B-GP
were	O
found	O
in	O
the	O
serum	O
of	O
77	O
patients	O
(	O
81	O
.	O
9	O
%)	O
with	O
a	O
mean	O
titer	O
of	O
63	O
.	O
9	O
±	O
50	O
.	O
8	O
U	O
/	O
mL	O
(	O
Table	O
3	O
).	O

Subgroup	O
analysis	O
of	O
BP	B-DS
patients	O
with	O
and	O
without	O
mucosal	O
involvement	O
showed	O
no	O
significant	O
difference	O
both	O
within	O
the	O
number	O
of	O
BP	B-DS
patients	O
who	O
produced	O
anti	O
-	O
BP180	B-GP
antibodies	B-GP
and	O
within	O
the	O
mean	O
serum	O
titer	O
for	O
this	O
autoantibody	B-GP
(	O
Table	O
3	O
).	O

In	O
BP	B-DS
patients	O
without	O
mucosal	O
involvement	O
at	O
baseline	O
,	O
serum	O
anti	O
-	O
BP180	B-GP
ELISA	O
values	O
were	O
significantly	O
correlated	O
with	O
all	O
BPDAI	O
scores	O
except	O
mucosal	O
BPDAI	O
,	O
i	O
.	O
e	O
.,	O
total	O
,	O
skin	O
,	O
blister	O
/	O
erosion	O
,	O
and	O
erythema	B-DS
/	O
urticaria	B-DS
BPDAI	O
scores	O
(	O
P	O
<	O
0	O
.	O
0001	O
,	O
Figures	O
3A	O
–	O
D	O
,	O
Table	O
4A	O
).	O

Serum	O
immunological	O
characteristics	O
of	O
patients	O
with	O
BP	B-DS
according	O
to	O
mucosal	O
involvement	O
.	O

All	O
BP	B-DS
patients	O

Patients	O
without	O
mucosal	O
involvement	O

Patients	O
with	O
mucosal	O
involvement	O

Pvalue	O

Serum	O
anti	O
-	O
BP180	B-GP
NC16A	O

Number	O
of	O
patients	O
(	O
n	O
)	O
a	O

94	O

76	O

18	O

NA	O

Number	O
of	O
patients	O
with	O
titer	O
≥	O
9	O
U	O
/	O
mL	O
,	O
n	O
(%)	O

77	O
(	O
81	O
.	O
9	O
)	O

62	O
(	O
81	O
.	O
6	O
)	O

15	O
(	O
83	O
.	O
3	O
)	O

0	O
.	O
86	O

Mean	O
value	O
±	O
SD	O
(	O
U	O
/	O
mL	O
)	O

63	O
.	O
9	O
±	O
50	O
.	O
8	O

62	O
±	O
50	O
.	O
1	O

71	O
.	O
9	O
±	O
54	O
.	O
4	O

0	O
.	O
53	O


Serum	O
anti	O
-	O
BP230	B-GP

Number	O
of	O
patients	O
(	O
n	O
)	O
b	O

93	O

75	O

18	O

NA	O

Number	O
of	O
patients	O
with	O
titer	O
≥	O
9	O
U	O
/	O
mL	O
,	O
n	O
(%)	O

44	O
(	O
47	O
.	O
3	O
)	O

39	O
(	O
52	O
)	O

5	O
(	O
27	O
.	O
8	O
)	O

0	O
.	O
06	O

Mean	O
value	O
±	O
SD	O
(	O
U	O
/	O
mL	O
)	O

29	O
.	O
1	O
±	O
37	O

32	O
.	O
2	O
±	O
37	O
.	O
8	O

16	O
.	O
2	O
±	O
30	O
.	O
9	O

0	O
.	O
07	O

Subsets	O
of	O
BP	B-DS
patients	O
with	O
or	O
without	O
mucosal	O
involvement	O
were	O
compared	O
and	O
P	O
-	O
value	O
was	O
obtained	O
using	O
Chi2	O
tests	O
for	O
comparison	O
between	O
qualitative	O
variables	O
and	O
nonparametric	O
,	O
Mann	O
–	O
Whitney	O
tests	O
for	O
comparison	O
between	O
quantitative	O
values	O
.	O

aPatients	O
for	O
whom	O
serum	O
anti	O
-	O
BP180	B-GP
ELISA	O
values	O
were	O
available	O
.	O

bPatients	O
for	O
whom	O
serum	O
anti	O
-	O
BP230	B-GP
ELISA	O
values	O
were	O
available	O
.	O

NA	O
,	O
not	O
applicable	O
;	O
BP	B-DS
,	O
bullous	B-DS
pemphigoid	I-DS
;	O
ELISA	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Correlation	O
of	O
serum	O
anti	O
-	O
BP180	B-GP
NC16A	O
titers	O
with	O
total	O
BP	B-DS
Disease	O
Area	O
Index	O
(	O
BPDAI	O
)	O
(	O
A	O
,	O
E	O
),	O
total	O
skin	O
BPDAI	O
(	O
B	O
,	O
F	O
),	O
blister	O
/	O
erosion	O
BPDAI	O
(	O
C	O
,	O
G	O
),	O
and	O
erythema	B-DS
/	O
urticaria	B-DS
BPDAI	O
(	O
D	O
,	O
H	O
)	O
scores	O
in	O
bullous	B-DS
pemphigoid	I-DS
patients	O
without	O
(	O
A	O
–	O
D	O
)	O
or	O
with	O
(	O
E	O
–	O
H	O
)	O
mucosal	O
involvement	O
.	O

The	O
correlation	O
coefficients	O
and	O
statistical	O
significances	O
were	O
calculated	O
according	O
to	O
Spearman	O
’	O
s	O
correlation	O
test	O
and	O
are	O
summarized	O
in	O
Table	O
4	O
.	O

Correlation	O
between	O
BPDAI	O
scores	O
and	O
serum	O
anti	O
-	O
BP180	B-GP
(	O
A	O
)	O
or	O
anti	O
-	O
BP230	B-GP
(	O
B	O
)	O
antibody	B-GP
titers	O
in	O
BP	B-DS
patients	O
according	O
to	O
mucosal	O
involvement	O
.	O

All	O
BP	B-DS
patients	O

Patients	O
without	O
mucosal	O
involvement	O

Patients	O
with	O
mucosal	O
involvement	O

(	O
A	O
)	O


Number	O
of	O
patients	O
(	O
n	O
)	O
a	O

94	O

76	O

18	O

Total	O
BPDAI	O

r	O
=	O
0	O
.	O
57	O

r	O
=	O
0	O
.	O
62	O

r	O
=	O
0	O
.	O
42	O

P	O
<	O
0	O
.	O
0001	O

P	O
<	O
0	O
.	O
0001	O

P	O
=	O
0	O
.	O
09	O

Total	O
skin	O
BPDAI	O

r	O
=	O
0	O
.	O
58	O

r	O
=	O
0	O
.	O
63	O

r	O
=	O
0	O
.	O
46	O

P	O
<	O
0	O
.	O
0001	O

P	O
<	O
0	O
.	O
0001	O

P	O
=	O
0	O
.	O
06	O

Skin	O
BPDAI	O
:	O
blisters	O
/	O
erosions	O

r	O
=	O
0	O
.	O
46	O

r	O
=	O
0	O
.	O
52	O

r	O
=	O
0	O
.	O
26	O

P	O
<	O
0	O
.	O
0001	O

P	O
<	O
0	O
.	O
0001	O

P	O
=	O
0	O
.	O
30	O

Skin	O
BPDAI	O
:	O
erythema	B-DS
/	O
urticaria	B-DS

r	O
=	O
0	O
.	O
52	O

r	O
=	O
0	O
.	O
53	O

r	O
=	O
0	O
.	O
52	O

P	O
<	O
0	O
.	O
0001	O

P	O
<	O
0	O
.	O
0001	O

P	O
=	O
0	O
.	O
03	O

Mucosal	O
BPDAI	O

r	O
=	O
0	O
.	O
07	O

NA	O

r	O
=	O
0	O
.	O
15	O

P	O
=	O
0	O
.	O
48	O

NA	O

P	O
=	O
0	O
.	O
55	O


(	O
B	O
)	O


Number	O
of	O
patients	O
(	O
n	O
)	O
b	O

93	O

75	O

18	O

Total	O
BPDAI	O

r	O
=	O
−	O
0	O
.	O
01	O

r	O
=	O
0	O
.	O
05	O

r	O
=	O
0	O
.	O
04	O

P	O
=	O
0	O
.	O
93	O

P	O
=	O
0	O
.	O
69	O

P	O
=	O
0	O
.	O
89	O

Total	O
skin	O
BPDAI	O

r	O
=	O
0	O
.	O
001	O

r	O
=	O
0	O
.	O
06	O

r	O
=	O
0	O
.	O
02	O

P	O
=	O
0	O
.	O
99	O

P	O
=	O
0	O
.	O
63	O

P	O
=	O
0	O
.	O
94	O

Skin	O
BPDAI	O
:	O
blisters	O
/	O
erosions	O

r	O
=	O
0	O
.	O
03	O

r	O
=	O
0	O
.	O
11	O

r	O
=	O
−	O
0	O
.	O
05	O

P	O
=	O
0	O
.	O
76	O

P	O
=	O
0	O
.	O
33	O

P	O
=	O
0	O
.	O
86	O

Skin	O
BPDAI	O
:	O
erythema	B-DS
/	O
urticaria	B-DS

r	O
=	O
0	O
.	O
01	O

r	O
=	O
−	O
0	O
.	O
01	O

r	O
=	O
0	O
.	O
21	O

P	O
=	O
0	O
.	O
89	O

P	O
=	O
0	O
.	O
9	O

P	O
=	O
0	O
.	O
41	O

Mucosal	O
BPDAI	O

r	O
=	O
−	O
0	O
.	O
20	O

NA	O

r	O
=	O
−	O
0	O
.	O
26	O

P	O
=	O
0	O
.	O
06	O

NA	O

P	O
=	O
0	O
.	O
31	O

Spearman	O
’	O
s	O
correlation	O
coefficient	O
was	O
used	O
to	O
explore	O
the	O
relationship	O
between	O
BPDAI	O
score	O
and	O
serum	O
autoantibody	B-GP
titers	O
.	O

aPatients	O
for	O
whom	O
serum	O
anti	O
-	O
BP180	B-GP
ELISA	O
values	O
were	O
available	O
.	O

bPatients	O
for	O
whom	O
serum	O
anti	O
-	O
BP230	B-GP
ELISA	O
values	O
were	O
available	O
.	O

NA	O
,	O
not	O
applicable	O
;	O
BP	B-DS
,	O
bullous	B-DS
pemphigoid	I-DS
;	O
BPDAI	O
,	O
BP	B-DS
Disease	O
Area	O
Index	O
;	O
ELISA	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

In	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
at	O
baseline	O
,	O
anti	O
-	O
BP180	B-GP
ELISA	O
values	O
were	O
only	O
correlated	O
with	O
the	O
erythema	B-DS
/	O
urticaria	B-DS
BPDAI	O
score	O
(	O
P	O
=	O
0	O
.	O
03	O
).	O

Within	O
this	O
subgroup	O
of	O
BP	B-DS
patients	O
,	O
only	O
a	O
correlation	O
tendency	O
was	O
observed	O
with	O
the	O
total	O
BPDAI	O
score	O
(	O
P	O
=	O
0	O
.	O
09	O
)	O
and	O
the	O
skin	O
BPDAI	O
score	O
(	O
P	O
=	O
0	O
.	O
06	O
),	O
whereas	O
no	O
correlation	O
could	O
be	O
drawn	O
with	O
the	O
blister	O
/	O
erosion	O
BPDAI	O
score	O
(	O
P	O
=	O
0	O
.	O
30	O
)	O
(	O
Figures	O
3E	O
–	O
H	O
,	O
Table	O
4A	O
).	O

Finally	O
,	O
no	O
correlation	O
was	O
found	O
between	O
the	O
mucous	O
membrane	O
part	O
of	O
BPDAI	O
score	O
and	O
the	O
anti	O
-	O
BP180	B-GP
-	O
NC16A	O
ELISA	O
values	O
.	O

Anti	O
-	O
BP230	B-GP
antibodies	B-GP
were	O
found	O
in	O
the	O
serum	O
of	O
44	O
BP	B-DS
patients	O
(	O
47	O
.	O
3	O
%)	O
with	O
a	O
mean	O
titer	O
of	O
29	O
.	O
1	O
±	O
37	O
U	O
/	O
mL	O
(	O
Table	O
3	O
).	O

Interestingly	O
,	O
39	O
BP	B-DS
patients	O
without	O
mucosal	O
involvement	O
(	O
52	O
%)	O
but	O
only	O
5	O
among	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
(	O
27	O
.	O
8	O
%)	O
had	O
a	O
positive	O
anti	O
-	O
BP230	B-GP
ELISA	O
value	O
(	O
P	O
=	O
0	O
.	O
06	O
).	O

Such	O
a	O
difference	O
tendency	O
was	O
also	O
observed	O
when	O
analyzing	O
the	O
anti	O
-	O
BP230	B-GP
mean	O
titer	O
(	O
32	O
.	O
2	O
±	O
37	O
.	O
8	O
and	O
16	O
.	O
2	O
±	O
30	O
.	O
9	O
U	O
/	O
mL	O
;	O
P	O
=	O
0	O
.	O
07	O
,	O
respectively	O
)	O
(	O
Table	O
3	O
).	O

At	O
baseline	O
,	O
anti	O
-	O
BP230	B-GP
antibody	B-GP
serum	O
concentrations	O
were	O
correlated	O
with	O
none	O
of	O
the	O
BPDAI	O
scores	O
within	O
these	O
two	O
groups	O
(	O
Table	O
4B	O
).	O

Factors	O
Associated	O
with	O
Mucosal	O
Involvement	O
in	O
BP	B-DS

In	O
univariate	O
analysis	O
,	O
clinical	O
features	O
associated	O
with	O
mucosal	O
involvement	O
at	O
baseline	O
were	O
a	O
number	O
of	O
daily	O
new	O
blisters	O
>	O
10	O
(	O
P	O
=	O
0	O
.	O
02	O
),	O
a	O
higher	O
total	O
,	O
skin	O
and	O
blister	O
/	O
erosion	O
BPDAI	O
(	O
P	O
=	O
0	O
.	O
004	O
,	O
P	O
=	O
0	O
.	O
02	O
,	O
P	O
=	O
0	O
.	O
001	O
,	O
respectively	O
),	O
and	O
a	O
severe	O
disease	O
according	O
BPDAI	O
(	O
P	O
=	O
0	O
.	O
04	O
).	O

The	O
absence	O
of	O
anti	O
-	O
BP230	B-GP
autoantibody	B-GP
also	O
showed	O
a	O
tendency	O
of	O
association	O
with	O
a	O
mucosal	O
involvement	O
(	O
P	O
=	O
0	O
.	O
08	O
).	O

By	O
contrast	O
,	O
univariate	O
analysis	O
revealed	O
no	O
relationship	O
between	O
anti	O
-	O
BP180	B-GP
autoantibody	B-GP
serum	O
concentration	O
and	O
mucosal	O
involvement	O
.	O

In	O
multivariate	O
analysis	O
,	O
the	O
absence	O
of	O
serum	O
anti	O
-	O
BP230	B-GP
autoantibody	B-GP
was	O
the	O
only	O
factor	O
independently	O
associated	O
with	O
mucosal	O
involvement	O
(	O
OR	O
7	O
.	O
8	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
1	O
–	O
19	O
.	O
6	O
)	O
(	O
P	O
<	O
0	O
.	O
0001	O
).	O

Discussion	O

This	O
study	O
is	O
the	O
first	O
one	O
to	O
compare	O
at	O
baseline	O
the	O
clinical	O
characteristics	O
by	O
means	O
of	O
the	O
BPDAI	O
score	O
along	O
with	O
the	O
concentrations	O
of	O
anti	O
-	O
BP180	B-GP
and	O
anti	O
-	O
BP230	B-GP
antibodies	B-GP
in	O
BP	B-DS
patients	O
with	O
and	O
without	O
mucosal	O
involvement	O
.	O

Analysis	O
of	O
separate	O
and	O
independent	O
BPDAI	O
sub	O
-	O
scores	O
highlighted	O
that	O
skin	B-DS
lesions	I-DS
,	O
more	O
specifically	O
blisters	O
,	O
and	O
erosions	O
were	O
more	O
substantial	O
in	O
patients	O
with	O
mucosal	O
involvement	O
than	O
in	O
typical	O
BP	B-DS
.	O

Such	O
clinical	O
characteristics	O
were	O
associated	O
with	O
the	O
absence	O
of	O
anti	O
-	O
BP230	B-GP
autoantibody	B-GP
in	O
the	O
serum	O
of	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
mucosal	O
lesions	O
are	O
clinically	O
mainly	O
related	O
to	O
disease	O
severity	O
,	O
but	O
not	O
only	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
compared	O
to	O
the	O
classical	O
pathophysiological	O
processes	O
previously	O
defined	O
in	O
BP	B-DS
(	O
12	O
,	O
16	O
,	O
17	O
,	O
24	O
,	O
33	O
–	O
36	O
),	O
specific	O
immunological	O
mechanisms	O
should	O
be	O
triggered	O
to	O
end	O
with	O
mucosal	O
lesions	O
.	O

In	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
,	O
skin	O
and	O
mucosal	O
lesions	O
are	O
likely	O
to	O
concomitantly	O
occur	O
during	O
the	O
disease	O
process	O
.	O

Although	O
our	O
results	O
showed	O
that	O
mucosal	O
involvement	O
in	O
BP	B-DS
was	O
associated	O
with	O
disease	O
severity	O
,	O
we	O
also	O
observed	O
mucosal	O
involvement	O
in	O
BP	B-DS
patient	O
with	O
mild	O
disease	O
.	O

Actually	O
,	O
there	O
was	O
a	O
broad	O
distribution	O
of	O
total	O
BPDAI	O
score	O
among	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
,	O
but	O
the	O
percentage	O
of	O
patients	O
with	O
mucosal	O
involvement	O
increased	O
along	O
with	O
the	O
BPDAI	O
values	O
(	O
Figure	O
1C	O
).	O

This	O
suggests	O
that	O
mucous	O
membrane	O
involvement	O
in	O
patients	O
with	O
mild	O
BP	B-DS
is	O
not	O
just	O
a	O
consequence	O
of	O
the	O
extent	O
or	O
severity	O
of	O
the	O
disease	O
,	O
and	O
therefore	O
that	O
some	O
BP	B-DS
patients	O
are	O
more	O
prone	O
to	O
develop	O
mucosal	O
lesions	O
than	O
others	O
.	O

Thus	O
,	O
we	O
can	O
speculate	O
that	O
specific	O
biological	O
/	O
immunological	O
mechanisms	O
responsible	O
for	O
these	O
lesions	O
are	O
activated	O
in	O
those	O
BP	B-DS
patients	O
.	O

This	O
further	O
raised	O
the	O
question	O
of	O
the	O
event	O
on	O
which	O
a	O
break	O
of	O
tolerance	O
outside	O
of	O
the	O
skin	O
tissue	O
could	O
originate	O
.	O

Occurrence	O
of	O
mucosal	O
lesions	O
in	O
some	O
patients	O
with	O
BP	B-DS
recalls	O
the	O
variation	O
in	O
the	O
number	O
of	O
sites	O
involved	O
in	O
patients	O
with	O
mucous	B-DS
membrane	I-DS
pemphigoid	I-DS
(	O
37	O
).	O

Previous	O
study	O
suggested	O
that	O
regulatory	O
T	O
(	O
Treg	O
)	O
cells	O
play	O
an	O
indispensable	O
role	O
in	O
maintaining	O
self	O
-	O
tolerance	O
in	O
BP	B-DS
leading	O
to	O
an	O
increase	O
in	O
autoreactive	O
Th2	O
,	O
Th1	O
,	O
and	O
B	O
cells	O
that	O
can	O
recognize	O
different	O
domains	O
of	O
BP180	B-GP
(	O
38	O
–	O
40	O
).	O

The	O
role	O
of	O
Treg	O
cells	O
in	O
pemphigoid	B-DS
diseases	O
was	O
further	O
demonstrated	O
by	O
mean	O
of	O
mice	B-OG
models	O
(	O
41	O
).	O

Although	O
Treg	O
cells	O
account	O
for	O
less	O
than	O
10	O
%	O
of	O
peripheral	O
CD4	B-GP
+	O
T	O
cells	O
,	O
recent	O
studies	O
have	O
reported	O
that	O
tissue	O
resident	O
Treg	O
cells	O
can	O
even	O
control	O
non	O
-	O
immunological	O
processes	O
.	O

Both	O
Treg	O
types	O
demonstrated	O
plasticity	O
and	O
can	O
convert	O
to	O
Th17	O
cells	O
according	O
to	O
the	O
cytokine	B-GP
environment	O
(	O
42	O
).	O

In	O
this	O
line	O
,	O
we	O
and	O
other	O
groups	O
demonstrated	O
the	O
presence	O
of	O
cytokines	B-GP
such	O
as	O
IL	B-GP
-	I-GP
1	I-GP
,	O
IL	B-GP
-	I-GP
6	I-GP
,	O
IL	B-GP
-	I-GP
23	I-GP
,	O
TGFβ	B-GP
,	O
etc	O
,	O
in	O
BP	B-DS
skin	B-DS
lesions	I-DS
.	O

We	O
also	O
demonstrated	O
that	O
the	O
cytokines	B-GP
panel	O
more	O
likely	O
originated	O
from	O
BP	B-DS
epiphenomenon	O
that	O
still	O
remained	O
to	O
be	O
elucidated	O
(	O
26	O
).	O

Such	O
variations	O
could	O
account	O
for	O
variations	O
in	O
a	O
deficit	O
in	O
Treg	O
cells	O
and	O
favor	O
the	O
development	O
of	O
tissue	O
damages	O
.	O

In	O
turn	O
,	O
skin	O
remodeling	O
could	O
impact	O
on	O
both	O
the	O
number	O
and	O
the	O
Treg	O
homing	O
at	O
different	O
levels	O
of	O
the	O
skin	O
compartments	O
.	O

Although	O
aging	O
has	O
been	O
associated	O
with	O
a	O
loss	O
of	O
central	O
immune	O
tolerance	O
in	O
elderly	O
patients	O
as	O
in	O
BP	B-DS
(	O
43	O
),	O
further	O
investigations	O
are	O
now	O
required	O
to	O
determine	O
the	O
events	O
specifically	O
responsible	O
for	O
the	O
mucosal	O
involvement	O
in	O
patients	O
with	O
BP	B-DS
,	O
especially	O
of	O
the	O
oral	O
cavity	O
.	O

Although	O
the	O
analysis	O
of	O
skin	O
BPDAI	O
highlighted	O
an	O
increase	O
in	O
the	O
blisters	O
/	O
erosions	O
activity	O
in	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
,	O
serum	O
titers	O
of	O
autoantibodies	B-GP
directed	O
against	O
BP180	B-GP
-	O
NC16A	O
,	O
the	O
dominant	O
autoantigen	B-GP
in	O
BP	B-DS
,	O
were	O
not	O
different	O
between	O
patients	O
with	O
and	O
without	O
mucosal	O
involvement	O
.	O

Of	O
note	O
,	O
Hofmann	O
et	O
al	O
.	O
showed	O
that	O
the	O
presence	O
of	O
autoantibodies	B-GP
against	O
both	O
the	O
BP180	B-GP
N	O
-	O
and	O
C	O
-	O
terminal	O
of	O
the	O
ectodomain	O
was	O
associated	O
with	O
the	O
presence	O
of	O
mucosal	O
lesions	O
(	O
44	O
).	O

Then	O
,	O
Di	O
Zenzo	O
et	O
al	O
.	O
(	O
21	O
)	O
and	O
Mariotti	O
et	O
al	O
.	O
(	O
45	O
)	O
found	O
that	O
autoantibody	B-GP
reactivity	O
against	O
three	O
extracellular	O
epitopes	O
of	O
BP180	B-GP
(	O
NC16A	O
,	O
AA	O
1	O
,	O
080	O
–	O
1	O
,	O
107	O
and	O
AA	O
1	O
,	O
331	O
–	O
1	O
,	O
404	O
)	O
appeared	O
to	O
be	O
related	O
to	O
the	O
presence	O
of	O
both	O
skin	O
and	O
mucosal	O
involvement	O
in	O
BP	B-DS
patients	O
.	O

By	O
contrast	O
,	O
in	O
our	O
study	O
,	O
the	O
uni	O
-	O
and	O
multivariate	O
analysis	O
highlighted	O
that	O
the	O
absence	O
of	O
anti	O
-	O
BP230	B-GP
antibody	B-GP
was	O
the	O
only	O
factor	O
independently	O
associated	O
with	O
mucosal	O
involvement	O
in	O
BP	B-DS
.	O

This	O
unconventional	O
result	O
could	O
imply	O
that	O
the	O
immune	O
response	O
may	O
be	O
shifted	O
toward	O
other	O
autoantibodies	B-GP
in	O
those	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
which	O
could	O
be	O
related	O
to	O
a	O
lower	O
threshold	O
of	O
tolerance	O
breakdown	O
in	O
line	O
with	O
a	O
reduced	O
level	O
of	O
Treg	O
cells	O
or	O
of	O
Treg	O
homing	O
as	O
mentioned	O
above	O
.	O

Based	O
on	O
a	O
recent	O
publication	O
(	O
20	O
),	O
we	O
can	O
hypothesize	O
that	O
the	O
loss	O
of	O
immune	O
tolerance	O
curbs	O
both	O
the	O
innate	O
and	O
the	O
adaptive	O
immune	O
responses	O
,	O
which	O
leads	O
to	O
the	O
release	O
of	O
a	O
specific	O
panel	O
of	O
proteases	B-GP
associated	O
with	O
blister	O
formation	O
and	O
tissue	O
remodeling	O
,	O
and	O
subsequently	O
to	O
a	O
shift	O
of	O
the	O
epitope	O
targeted	O
as	O
compared	O
with	O
the	O
classical	O
pathophysiological	O
mechanisms	O
associated	O
with	O
BP	B-DS
.	O

Altogether	O
,	O
this	O
could	O
be	O
reflected	O
by	O
a	O
reduced	O
activity	O
of	O
the	O
adaptive	O
immune	O
response	O
toward	O
the	O
hemidesmosomal	O
proteins	O
of	O
the	O
basal	O
keratinocyte	O
layer	O
and	O
an	O
increased	O
activity	O
toward	O
the	O
antigenic	O
cryptic	O
domains	O
of	O
molecules	O
involved	O
in	O
the	O
anchoring	O
of	O
those	O
basal	O
keratinocyte	O
to	O
the	O
basal	O
membrane	O
structure	O
.	O

To	O
address	O
those	O
mechanisms	O
,	O
it	O
would	O
be	O
relevant	O
to	O
compare	O
in	O
future	O
prospective	O
studies	O
the	O
number	O
and	O
the	O
activity	O
of	O
Treg	O
in	O
biopsy	O
specimens	O
from	O
either	O
skin	O
or	O
mucosa	O
BP	B-DS
lesions	O
with	O
others	O
samples	O
collected	O
from	O
patients	O
with	O
inflammatory	O
non	O
-	O
autoimmune	B-DS
diseases	I-DS
.	O

The	O
presence	O
of	O
other	O
autoantibodies	B-GP
may	O
interfere	O
with	O
the	O
classical	O
pathophysiological	O
process	O
of	O
BP	B-DS
(	O
12	O
,	O
16	O
,	O
17	O
,	O
24	O
,	O
33	O
–	O
36	O
,	O
46	O
).	O

In	O
BP	B-DS
patients	O
without	O
mucosal	O
involvement	O
,	O
the	O
serum	O
concentration	O
of	O
anti	O
-	O
BP180	B-GP
NC16A	O
autoantibodies	B-GP
was	O
well	O
correlated	O
with	O
both	O
the	O
skin	O
erythema	B-DS
/	O
urticaria	B-DS
and	O
the	O
blisters	O
/	O
erosions	O
BPDAI	O
scores	O
,	O
which	O
is	O
in	O
line	O
with	O
the	O
fact	O
that	O
anti	O
-	O
BP180	B-GP
autoantibody	B-GP
binding	O
onto	O
their	O
target	O
induced	O
an	O
inflammatory	O
response	O
leading	O
to	O
blister	O
formation	O
(	O
14	O
–	O
18	O
).	O

By	O
contrast	O
,	O
the	O
correlation	O
between	O
anti	O
-	O
BP180	B-GP
autoantibody	B-GP
titer	O
and	O
the	O
skin	O
blisters	O
/	O
erosions	O
BPDAI	O
score	O
was	O
not	O
evidenced	O
for	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
.	O

Of	O
note	O
,	O
the	O
BPDAI	O
investigated	O
the	O
presence	O
of	O
both	O
blisters	O
and	O
erosions	O
.	O

Thus	O
,	O
considering	O
that	O
the	O
number	O
of	O
daily	O
new	O
blisters	O
only	O
displayed	O
a	O
higher	O
tendency	O
in	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
,	O
the	O
highly	O
significant	O
difference	O
in	O
the	O
BPDAI	O
scores	O
associated	O
to	O
blisters	O
and	O
erosions	O
lesions	O
may	O
be	O
related	O
to	O
the	O
presence	O
of	O
erosions	O
rather	O
than	O
to	O
new	O
blisters	O
.	O

This	O
implies	O
that	O
the	O
mechanisms	O
leading	O
to	O
skin	O
blisters	O
/	O
erosions	O
and	O
maybe	O
to	O
mucosal	O
involvement	O
too	O
,	O
rely	O
on	O
either	O
different	O
or	O
additional	O
trigger	O
than	O
anti	O
-	O
BP180	B-GP
-	O
NC16A	O
autoantibodies	B-GP
in	O
BP	B-DS
patients	O
with	O
mucosal	O
lesion	O
.	O

It	O
was	O
proposed	O
that	O
differential	O
epitope	O
recognition	O
of	O
BP180	B-GP
could	O
be	O
associated	O
with	O
distinct	O
clinical	O
severity	O
(	O
5	O
).	O

However	O
,	O
additional	O
studies	O
are	O
necessary	O
to	O
define	O
the	O
panel	O
of	O
autoantibodies	B-GP
associated	O
with	O
BP	B-DS
with	O
mucosal	O
lesions	O
,	O
to	O
decipher	O
the	O
pathogenic	O
role	O
of	O
these	O
autoantibodies	B-GP
as	O
well	O
the	O
immunologic	O
mechanisms	O
associated	O
to	O
their	O
production	O
.	O

Several	O
limitations	O
of	O
the	O
study	O
are	O
to	O
be	O
acknowledged	O
,	O
mainly	O
its	O
relatively	O
limited	O
number	O
of	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
.	O

However	O
,	O
the	O
prospective	O
collection	O
of	O
clinical	O
data	O
including	O
BPDAI	O
assessment	O
allowed	O
a	O
good	O
evaluation	O
of	O
the	O
percentage	O
of	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
,	O
which	O
was	O
very	O
close	O
to	O
results	O
from	O
previous	O
large	O
series	O
of	O
BP	B-DS
patients	O
(	O
5	O
,	O
6	O
,	O
21	O
,	O
32	O
,	O
44	O
,	O
45	O
)	O
and	O
from	O
a	O
recent	O
retrospective	O
study	O
performed	O
in	O
our	O
dermatology	O
department	O
(	O
manuscript	O
under	O
consideration	O
).	O

Another	O
weakness	O
is	O
the	O
lack	O
of	O
investigations	O
regarding	O
biopsy	O
specimens	O
or	O
BFs	O
from	O
oral	O
mucous	O
membrane	O
for	O
pathophysiological	O
purpose	O
.	O

Unfortunately	O
,	O
recent	O
intact	O
oral	O
blisters	O
were	O
rare	O
and	O
too	O
transient	O
for	O
an	O
effective	O
,	O
systematic	O
sampling	O
.	O

To	O
avoid	O
biases	O
,	O
our	O
present	O
results	O
were	O
based	O
on	O
clinical	O
or	O
biological	O
data	O
which	O
could	O
systematically	O
be	O
collected	O
in	O
all	O
consecutive	O
patients	O
.	O

Although	O
we	O
observed	O
that	O
mucosal	O
involvement	O
also	O
occurred	O
in	O
patients	O
with	O
mild	O
or	O
moderate	O
disease	O
,	O
we	O
here	O
showed	O
that	O
mucosal	O
involvement	O
was	O
more	O
frequent	O
in	O
patients	O
with	O
severe	O
BP	B-DS
according	O
to	O
the	O
BPDAI	O
score	O
.	O

Actually	O
,	O
in	O
those	O
severe	O
BP	B-DS
patients	O
,	O
mucosal	O
involvement	O
could	O
represent	O
a	O
severity	O
criterion	O
but	O
not	O
a	O
clinical	O
atypia	O
.	O

Considering	O
all	O
elements	O
discussed	O
above	O
,	O
further	O
investigations	O
should	O
help	O
defining	O
the	O
pathophysiological	O
particularities	O
of	O
severe	O
BP	B-DS
patients	O
with	O
mucosal	O
involvement	O
.	O

Finally	O
,	O
in	O
patients	O
with	O
moderate	O
or	O
minimal	O
BP	B-DS
disease	O
,	O
other	O
diagnoses	O
could	O
be	O
considered	O
,	O
including	O
anti	O
-	O
P200	B-GP
pemphigoid	B-DS
and	O
epidermolysis	B-DS
bullosa	I-DS
acquisita	I-DS
,	O
which	O
was	O
very	O
unlikely	O
in	O
our	O
present	O
series	O
since	O
indirect	O
immunofluorescence	O
on	O
salt	O
-	O
split	O
skin	O
was	O
either	O
positive	O
with	O
labeling	O
of	O
the	O
epidermal	O
side	O
of	O
the	O
cleavage	O
or	O
negative	O
.	O

The	O
latter	O
BP	B-DS
patients	O
may	O
represent	O
an	O
interesting	O
subset	O
of	O
patients	O
to	O
identify	O
in	O
future	O
studies	O
the	O
specific	O
mechanisms	O
responsible	O
for	O
mucous	O
membrane	O
lesions	O
with	O
the	O
ultimate	O
goal	O
to	O
propose	O
innovative	O
targeted	O
therapy	O
to	O
preserve	O
the	O
quality	O
of	O
life	O
for	O
those	O
elderly	O
fragile	O
patients	O
.	O

Ethics	O
Statement	O

This	O
study	O
was	O
carried	O
out	O
in	O
accordance	O
with	O
the	O
recommendations	O
of	O
the	O
“	O
Commission	O
Nationale	O
de	O
l	O
’	O
Informatique	O
et	O
des	O
libertés	O
(	O
CNIL	O
,	O
authorization	O
DR	O
-	O
2013	O
-	O
320	O
)”	O
and	O
approved	O
by	O
the	O
Ethic	O
Committee	O
of	O
the	O
University	O
Hospital	O
of	O
Reims	O
.	O

All	O
subjects	O
gave	O
written	O
informed	O
consent	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Author	O
Contributions	O

FA	O
,	O
PB	O
,	O
and	O
B	O
-	O
NP	O
designed	O
the	O
study	O
.	O

AC	O
,	O
CM	O
,	O
GG	O
,	O
SJ	O
,	O
and	O
CB	O
performed	O
experiments	O
and	O
analyzed	O
clinical	O
and	O
biological	O
data	O
.	O

AC	O
,	O
FA	O
,	O
and	O
PB	O
wrote	O
the	O
manuscript	O
.	O

All	O
authors	O
critically	O
evaluated	O
the	O
data	O
and	O
approved	O
the	O
final	O
version	O
for	O
publication	O
.	O

Conflict	O
of	O
Interest	O
Statement	O

The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O

